Webinar: Panel Discussion: Improving Collaboration Between Industry and Academia by InsideScientific

Panel Discussion: Improving Collaboration Between Industry and Academia

About

As the field of CAR T cell therapy evolves, fostering effective collaborations between academic institutions and the biotechnology industry is essential to overcoming existing challenges and enhancing therapeutic outcomes.

Join us for this interactive breakout session and panel discussion exploring real-world examples of successful partnerships, new research tools available, and insights into regulatory compliance.

Key Topics Will Include:

Existing Collaborations in CAR T Research

Challenges and Opportunities in CAR T research

Navigating Regulatory and Material Qualification

Presenters

Nooshin Tabatabaei-Zavareh

Associate Director, Immune Cell Culture, STEMCELL Technologies

Dr. Nooshin Tabatabaei-Zavareh received her PhD in Immunology at the University of British Columbia where she studied lymphopoiesis and NK cell development. Over the past 15 years, she has contributed to the development of products for immunology research at STEMCELL. Currently, Nooshin leads the Immunology, Culture & Applications Team providing solutions for the generation, expansion, and differentiation of immune cells.

Patrick Hanley, PhD

Chief and Director, Cellular Therapy Program; Associate Professor of Pediatrics

Dr. Hanley is the Chief and Director of the Cellular Therapy Program and an associate professor of pediatrics at Children’s National Hospital and the George Washington University, respectively. He oversees processing for standard of care stem cell transplantation as well as the development, manufacture, quality, and testing of novel cell and gene therapies.

Julian J. Lum, PhD

Distinguished Scientist. Professor Deeley Research Centre, BC Cancer. University of Victoria

Dr. Julian J. Lum obtained his PhD in Immunology from the University of Ottawa. His lab at Deeley Research Centre at BC Cancer focuses on identifying metabolic targets for cell-based immunotherapy, where Dr. Lum’s core approach is to metabolically engineer CAR T cells using CRISPR-Cas-based gene-editing to overcome metabolic barriers in the tumor microenvironment.

Lynn Csontos

Vice President, Regulatory Affairs,

Lynn Csontos, Vice President of Regulatory Affairs at STEMCELL Technologies, has worked in the biotechnology industry for over 25 years. Her background is primarily with small molecule API and drug products, and she uses that knowledge to navigate the regulatory landscape currently being defined for cellular, gene, and tissue engineered therapies.

Dominika Nackiewicz, PhD

Product Manager, Immunology, STEMCELL Technologies

Dr. Nackiewicz received her PhD in Experimental Medicine from The University of British Columbia and received additional immunology training at University of Virginia and Yale University. She is currently a Product Manager for immunology and immune cell culture applications at STEMCELL Technologies, where she helps to convert new ideas into innovative, reliable products.

Reserve Your Spot

First Name*

Last Name*

Email Address*

Organization / Company*

Job Title*

Country / Region*

At which stage of research are you currently?*

Fundamental research

Early preclinical

Late preclinical/process development

Clinical (Phase I–III)

Commercialization

I don't know

Not applicable

What part of your T cell workflow do you find the most challenging? *

Cell sourcing

Cell isolation

Cell expansion

Cell activation

Cell engineering

Other

I do not work with T cells

Please post any questions you might have for the speakers in the field below:

utm_bmcr_source